While a large portion of cancer immunotherapies focus on antibodies targeting T cells, developers are now exploring newer therapeutic agents and approaches. The Immunotherapy channel highlights cutting-edge discovery approaches harnessing NK cells for improved cell therapies, tailoring the microbiome for immune response, and targeting myeloid infiltrates in the tumor microenvironment, as well as the discovery and design of new immunomodulatory small molecules.

September 26-27
September 27-28